Benevolent News Hub

In the media
News
Rob Quinn To Join BenevolentAI As Chief Financial Officer in January 2021
We are thrilled to be welcoming Rob Quinn to the BenevolentAI team as our new Chief Finance Officer from January 2021
Oct 21, 2020
Blog
Data Diversity: Ten practical approaches to acquiring the right datasets Part 1
In this two-part blog, we propose ten practical approaches to improving data acquisition to encourage more inclusive research and improve the diversity of data used in drug discovery.
Oct 20, 2020
Blog
Data Diversity: Ten practical approaches to acquire the right datasets Part 2
In this two-part blog, we propose ten practical approaches to improving data acquisition to encourage more inclusive research and improve the diversity of data used in drug discovery.
Oct 20, 2020
News
NIAID releases additional data validating BenevolentAI’s hypothesis for baricitinib as a treatment for COVID-19 patients in large-scale randomised control trial
Additional data from the ACTT-2 randomised control trial shows reduced time to recovery and improved clinical outcomes for patients with COVID-19.
Oct 9, 2020
News
BenevolentAI welcomes Professor Russ Altman as scientific advisor
As a scientific advisor at BenevolentAI, Professor Russ Altman will help our scientists to further push the boundaries of machine learning applied drug discovery.
Oct 1, 2020
Blog
The Diversity Analysis Tool: Towards better Diversity in Data for Precision Medicine
As part of the data diversity initiative, our team released a simple open-source programme to evaluate the diversity of datasets and inspire others to search for solutions to drive innovation that benefits everyone.
Sep 22, 2020
News
BenevolentAI’s platform-derived hypothesis for COVID-19 treatment validated in US NIAID randomised control trial
NIAID trial shows baricitinib in combination with remdesivir reduces the recovery time in patients hospitalised with COVID-19, validating BenevolentAI’s AI-derived hypothesis.
Sep 14, 2020
Blog
Building the next generation of leaders with Circl
BenevolentAI Director of Talent Acquisition and Development, Yasmina Rahiman, explores the power of coaching for leadership development in technology.
Aug 21, 2020
News
Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19
Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients
Jul 1, 2020
News
COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair
David Sinclair and colleagues review our recent publication in the EMBO Molecular Medicine Journal in support of our AI-derived hypothesis for a potential treatment of COVID-19.
Jul 1, 2020